San Diego-based Otonomy, which is developing treatments for Meniere’s disease, said today that it has raised $10M in a Series A financing round. The round came from Avalon Ventures. According to Otonomy, the funding will go towards supporting the ongoing clinical trial for its compound, to initiate IND studies for a second compound, and early-stage development of a third program. Otonomy is headed by Jay Lichter, who is also a managing director at Avalon Ventures. Otonomy’s first product is a sustained release formulation of steroid dexamethasone.
Menieres Help Comment:
In the 12 years of support work and 7 years of research and study into triggers and causes of Menieres it has become obvious that money is often found to fund research into “treatments” (ie. drugs/vaccines/surgical options) but never to actually find the root cause and therefore a definitive cure. That said, we now know enough that you can find your own root cause(s) and take action yourself to rid yourself of Meniere’s, period!